{
  "id": "CD015003.PUB2",
  "draft": "Can colchicine help prevent heart attacks, strokes, and other cardiovascular events in people who have not had any of these problems before? We looked at the evidence to find out. Colchicine is a cheap drug with anti-inflammatory properties that has been used for centuries. It might help prevent heart and blood vessel problems because it can reduce inflammation, a key factor in the development of the disease. However, we still do not know if colchicine can prevent these heart and blood vessel problems for most people. We need more and better research to find out its true benefits and harms.\n\nWhat are the key messages of this review? \n- Colchicine may reduce the risk of death from any cause, but this finding is very uncertain.\n- It may also increase the risk of diarrhoea.\n- We do not know if colchicine can prevent heart attacks, strokes, or other cardiovascular events in people without a history of these problems.\n\nWhat is heart and blood vessel disease? \nHeart and blood vessel disease is a condition where arteries become clogged with fatty substances. This process involves long-term swelling (inflammation) inside the arteries. Because this disease involves inflammation, we wanted to find out if colchicine, an anti-inflammatory drug, could help prevent it.\n\nWhat did the review authors want to find out? \nWe wanted to find out the benefits and harms of using colchicine to prevent cardiovascular events in people who have not had these problems before. We looked at studies that compared colchicine with a placebo, other medicines that affect the immune system, or usual care.\n\nHow did we find the evidence? \nWe searched for studies that compared colchicine to other treatments for preventing cardiovascular events. We summarized the results and rated how confident we are in the evidence.\n\nWhat did we find? \nWe found 15 studies that involved 1721 people. The studies lasted from 4 to 728 weeks. In these studies, researchers compared people taking colchicine by mouth to people taking a placebo, other anti-inflammatory drugs, or having usual care. Most of the studies focused on liver disease rather than the general population. Colchicine may reduce the risk of death from any cause, but we are very uncertain about the results. It may make little to no difference to the risk of non-fatal heart attacks, but we are very uncertain about the results. Colchicine may increase the risk of diarrhoea. For every 10 people treated with colchicine, 1 extra person may get diarrhoea, compared to those not taking colchicine.\n\nWhat are the limitations of this evidence? \nThe evidence is not strong for a few reasons. In almost all of the studies, people and their doctors knew which treatment they were getting. The review authors found this created a high risk of bias, which makes the results less reliable.\n\nHow up to date is this evidence? \nThe evidence is up to date to May 2023.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 503,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 33,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 15.242424242424242,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 9,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 51,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 38,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 15,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "nouns": {
          "value": 126,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "flesch_reading_ease": {
          "value": 65.55717995059946,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 7.902060365082235,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 7.924631604313511,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 9.39021868787276,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 11.663570094584012,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 39.298090246400385,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 3.6666666666666665,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 11.12403840463596,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "dale_chall_readability": {
          "value": 5.810079908428219,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words_dc": {
          "value": 161,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "complex_words": {
          "value": 70,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "long_words": {
          "value": 121,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        }
      },
      "word_count_status": {
        "word_count": 503,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 503 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 9,
        "P50_count": 3,
        "P75_count": 6,
        "P90_count": 0,
        "P10_count": 0,
        "BEYOND_P90_count": 0,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 50,
        "P50_percentage": 16.666666666666664,
        "P75_percentage": 33.33333333333333,
        "P90_percentage": 0,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 0,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 83.33333333333334,
        "overall_assessment": "HIGHLY CONFORMS TO TYPICAL PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "This is a strong draft with excellent readability scores, but it needs a few key improvements to ensure patients can fully understand the limitations of the evidence. All critical checks for structure, format, and word count passed. However, the summary is not approved because it needs to better explain *why* the evidence is so uncertain.\n\nHere are the top 3 improvements needed:\n\n**1. Clarify Why the Study Population Limits the Findings**\n\n*   **Problematic Text:** In the 'What did we find?' section, you state: \"Most of the studies focused on liver disease rather than the general population.\"\n*   **Why it's a problem:** This is a critical limitation, but its importance is lost by being placed in the results section. Readers may not understand that this makes the evidence largely irrelevant to the review's main question. This point should be the centerpiece of the 'Limitations' section.\n*   **Suggested Rewrite:** Move this information to the 'What are the limitations of this evidence?' section and explain its impact more directly. For example: \"The main reason the evidence is not strong is that the people in the studies were not the focus of our review. We wanted to know about preventing heart problems in the general population, but many of the studies we found focused on people with liver disease. This makes it very difficult to know if the results apply to most people.\"\n\n**2. Explain 'Risk of Bias' in Simpler Terms**\n\n*   **Problematic Text:** \"In almost all of the studies, people and their doctors knew which treatment they were getting. The review authors found this created a high risk of bias, which makes the results less reliable.\"\n*   **Why it's a problem:** While you correctly identify the bias, you don't explain *why* it's a problem in simple terms. A lay reader may not understand the concept of blinding or the placebo effect.\n*   **Suggested Rewrite:** Explain the reasoning behind the bias. For example: \"In most studies, both the patients and their doctors knew who was receiving colchicine. This can influence the results, because people's expectations can affect how they report their health. Studies are more reliable when no one knows who is getting the real treatment until the end.\"\n\n**3. Make the Diarrhoea Risk Statistic More Concrete**\n\n*   **Problematic Text:** \"For every 10 people treated with colchicine, 1 extra person may get diarrhoea, compared to those not taking colchicine.\"\n*   **Why it's a problem:** This phrasing, based on the 'Number Needed to Harm', is statistically correct but can be hard for readers to visualize. Providing a comparison with absolute numbers is often more intuitive.\n*   **Suggested Rewrite:** Frame the statistic as a direct comparison. For example: \"Colchicine may increase the risk of diarrhoea. Based on the evidence, if 100 people took a placebo, about 3 might get diarrhoea. If 100 people took colchicine, that number might increase to about 13.\"\n",
      "pls_evaluation_summary": "The linguistic analysis shows this draft highly conforms to the statistical patterns of a typical PLS. An impressive 83% of the metrics, including all readability scores (Flesch-Kincaid Grade: 7.9), sentence length (15.2 words), and passive voice (9 instances), fall within the best quartile of our corpus. This indicates the writing is clear, concise, and uses an appropriate style. The feedback provided focuses on improving the context and explanation of key findings, which are areas that statistical metrics cannot fully assess."
    }
  ]
}